Skip to main content
SpringerLink
Log in

Primäre Systemtherapie des Ovarialkarzinoms

Primary systemic therapy of ovarian cancer

  • Leitthema
  • Published:
Der Gynäkologe Aims and scope

Zusammenfassung

Standardprimärtherapie bei Patientinnen mit fortgeschrittenem Ovarialkarzinom ist die intravenöse Chemotherapie mit Carboplatin und Paclitaxel. Bei Patientinnen im FIGO-Stadium IIIB–IV kann eine zusätzliche Gabe von Bevacizumab erwogen werden. Eine neoadjuvante, primäre Chemotherapie ohne vorherige Debulking-Operation sollte nicht durchgeführt werden. Intraperitoneale Therapieverfahren einschließlich HIPEC sollen nur im Rahmen von klinischen Studien erfolgen.

Abstract

Standard primary systemic treatment of patients with advanced ovarian cancer comprises six courses of intravenously administered carboplatin and paclitaxel. In patients with FIGO stage IIIB–IV disease, additional treatment with bevacizumab is possible. Primary, neoadjuvant treatment without prior debulking surgery should be avoided. Intraperitoneal treatments, including HIPEC, should only be given within controlled clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. AWMF (2013) S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren. AWMF-Register-Nummer 032-035OL. Langversion 1.0

  2. International Collaborative Ovarian Neoplasm (ICON) Collaborators (2003) International Collaborative Ovarian Neoplasm Trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst 95:125–132

    Article  Google Scholar 

  3. Trimbos JB, Vergote I, Bolis G et al (2003) Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst 95:113–125

    Article  PubMed  CAS  Google Scholar 

  4. Bois A du, Lück HJ, Meier W et al (2003) A randomized clinical trial of-cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95(17):1320–1329

    Article  PubMed  Google Scholar 

  5. Ozols RF, Bundy BN, Greer BE et al (2003) Phase III trial of carboplatin and paclitaxel compared with-cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21(17):3194–3200

    Article  PubMed  CAS  Google Scholar 

  6. Lindemann K, Christensen RD, Vergote I et al (2012) First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC) – a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG. Ann Oncol 23(10):2613–2619

    Article  PubMed  CAS  Google Scholar 

  7. Bois A du, Weber B, Rochon J et al (2006) Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens. J Clin Oncol 24(7):1127–1135

    Article  PubMed  Google Scholar 

  8. Pfisterer J, Weber B, Reuss A et al (2006) Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst 98(15):1036–1045

    Article  PubMed  CAS  Google Scholar 

  9. Hoskins P, Vergote I, Cervantes A et al (2010) Advanced ovarian cancer: phase III randomized study of sequential-cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel. J Natl Cancer Inst 102(20):1547–1556

    Article  PubMed  CAS  Google Scholar 

  10. Bois A du, Herrstedt J, Hardy-Bessard AC et al (2010) Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J Clin Oncol 28(27):4162–4169

    Article  PubMed  Google Scholar 

  11. Bookman MA, Brady MF, McGuire WP et al (2009) Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 27(9):1419–1425

    Article  PubMed  CAS  Google Scholar 

  12. Katsumata N, Yasuda M, Takahashi F et al (2009) Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 374(9698):1331–1338

    Article  PubMed  CAS  Google Scholar 

  13. Katsumata N, Yasuda M, Isonishi S et al (2012) Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. J Clin Oncol 30(suppl; abstr 5003)

  14. Burger RA, Brady MF, Bookman MA et al (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365(26):2473–2483

    Article  PubMed  CAS  Google Scholar 

  15. Perren TJ, Swart AM, Pfisterer J et al (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365(26):2484–2496

    Article  PubMed  CAS  Google Scholar 

  16. Monk BJ, Huang HQ, Burger RA et al (2013) Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer. Gynecol Oncol 128:573–578

    Article  PubMed  CAS  Google Scholar 

  17. Stark D, Nankivell M, Pujade-Lauraine E et al (2013) Standard chemotherapy with or without bevacizumab in advanced ovari-an cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Lancet Oncol 14:236–243

    Article  PubMed  Google Scholar 

  18. Burg ME van der, Lent M van, Buyse M et al (1995) The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 332:629–634

    Article  PubMed  Google Scholar 

  19. Rose PG, Nerenstone S, Brady MF et al (2004) Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 351:2489–2497

    Article  PubMed  CAS  Google Scholar 

  20. Vergote I, Tropé CG, Amant F et al (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363:943–953

    Article  PubMed  CAS  Google Scholar 

  21. Markman M, Bundy BN, Alberts DS et al (2001) Phase III trial of standard-dose intravenous-cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal-cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19:1001–1007

    PubMed  CAS  Google Scholar 

  22. Armstrong DK, Bundy B, Wenzel L et al (2006) Intraperitoneal-cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34–43

    Article  PubMed  CAS  Google Scholar 

Download references

Einhaltung der ethischen Richtlinien

Interessenkonflikt. J. Pfisterer, F. Hilpert, S. Mahner, P. Harter und A. du Bois geben an, dass kein Interessenkonflikt besteht. Alle angewandten Verfahren stehen im Einklang mit den ethischen Normen der verantwortlichen Kommission für Forschung am Menschen (institutionell und national) und mit der Deklaration von Helsinki von 1975 in der revidierten Fassung von 2008. Alle Patienten wurden erst nach erfolgter Aufklärung und Einwilligung in die Studie eingeschlossen.

Author information

Authors and Affiliations

  1. Zentrum für Gynäkologische Onkologie Kiel, Herzog-Friedrich-Str. 21, 24103, Kiel, Deutschland

    J. Pfisterer

  2. Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum Schleswig Holstein Campus Kiel, Kiel, Deutschland

    F. Hilpert

  3. Klinik für Gynäkologie, Universitätsklinikum Hamburg Eppendorf, Hamburg, Deutschland

    S. Mahner

  4. Klinik für Gynäkologie und Gynäkologische Onkologie, Kliniken Essen Mitte, Essen, Deutschland

    P. Harter & A. du Bois

Authors
  1. J. Pfisterer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Hilpert
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Mahner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. Harter
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. du Bois
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Pfisterer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pfisterer, J., Hilpert, F., Mahner, S. et al. Primäre Systemtherapie des Ovarialkarzinoms. Gynäkologe 46, 541–546 (2013). https://doi.org/10.1007/s00129-012-3113-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00129-012-3113-7

Schlüsselwörter

Keywords

Search

Navigation